Modern treatment of patients with arterial hypertension and chronic coronary syndrome Review article
Article Sidebar
Published:
Dec 31, 2021
Keywords:
arterial hypertension, chronic coronary syndrome, pharmacotherapy, lifestyle modification
Main Article Content
Abstract
Approximately 1,2 billion people worldwide suffer from arterial hypertension. Among these patients, less than half receive effective treatment. Poor blood pressure control contributes to the development of complications such as stroke or coronary artery disease. A patient with such complications automatically becomes a patient at very high cardiovascular risk, and thus requires personalized and effective treatment, not only of hypertension, but also of its complications. Despite the advancement of the disease, lifestyle modification and correct choice of pharmacotherapy can protect the patient from developing heart failure and prevent acute cardiovascular events.
Article Details
How to Cite
Łukasiewicz , M., & Mamcarz , A. (2021). Modern treatment of patients with arterial hypertension and chronic coronary syndrome. Medycyna Faktow (J EBM), 14(4(53), 378-383. https://doi.org/10.24292/01.MF.0421.6
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zhou B, Carrillo-Larco RM, Danaei G et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021. https://doi.org/10.1016/S0140- 6736(21)01330-1.
2. www.who.int (access: 23.08.2021).
3. NFZ o zdrowiu. Nadciśnienie tętnicze. Warszawa 2019 (access: 22.08.2021).
4. NFZ o zdrowiu. Choroba niedokrwienna serca. Warszawa 2020 (access: 22.08.2021).
5. Knuuti J, Wijns W, Saraste A et al. Wytyczne ESC dotyczące rozpoznawania i leczenia przewlekłych zespołów wieńcowych (2019). Kardiol Pol. Zeszyty Edukacyjne. 2020; 1.
6. Khan MA, Hashim MJ, Mustafa H et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020; 12(7): e9349.
7. Gajewski P (ed). Interna Szczeklika 2020. Medycyna Praktyczna, Kraków 2020.
8. Chrysant SG. A new paradigm in the treatment of the cardiovascular disease continuum: focus on prevention. Hippokratia. 2011; 15(1): 7-11.
9. Dzau VJ, Antman EM, Black HR et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006; 114(25): 2850-70.
10. Williams B, Mancia G, Spiering W et al. Wytyczne ESC/ESH dotyczące postępowania w nadciśnieniu tętniczym (2018). Kardiol Pol. 2019; 77(2): 71-159.
11. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciś Tęt. 2019; 23: 41-87.
12. Boden WE, O’Rourke RA, Teo KK et al. COURAGE Trial Research Group: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356: 1503-16.
13. Shaw LJ, Berman DS, Maron DJ et al. COURAGE Investigators: Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008; 117: 1283-91.
14. Piepoli M, Hoes A, Agewall S et al. Wytyczne ESC dotyczące prewencji chorób układu sercowo-naczyniowego w praktyce klinicznej (2016). Kardiol Pol. 2016; 74(9): 821-936.
15. Borghi C, Cicero AF, Ambrosioni E. Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vasc Health Risk Manag. 2008; 4(3): 665-71.
2. www.who.int (access: 23.08.2021).
3. NFZ o zdrowiu. Nadciśnienie tętnicze. Warszawa 2019 (access: 22.08.2021).
4. NFZ o zdrowiu. Choroba niedokrwienna serca. Warszawa 2020 (access: 22.08.2021).
5. Knuuti J, Wijns W, Saraste A et al. Wytyczne ESC dotyczące rozpoznawania i leczenia przewlekłych zespołów wieńcowych (2019). Kardiol Pol. Zeszyty Edukacyjne. 2020; 1.
6. Khan MA, Hashim MJ, Mustafa H et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020; 12(7): e9349.
7. Gajewski P (ed). Interna Szczeklika 2020. Medycyna Praktyczna, Kraków 2020.
8. Chrysant SG. A new paradigm in the treatment of the cardiovascular disease continuum: focus on prevention. Hippokratia. 2011; 15(1): 7-11.
9. Dzau VJ, Antman EM, Black HR et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006; 114(25): 2850-70.
10. Williams B, Mancia G, Spiering W et al. Wytyczne ESC/ESH dotyczące postępowania w nadciśnieniu tętniczym (2018). Kardiol Pol. 2019; 77(2): 71-159.
11. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciś Tęt. 2019; 23: 41-87.
12. Boden WE, O’Rourke RA, Teo KK et al. COURAGE Trial Research Group: Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356: 1503-16.
13. Shaw LJ, Berman DS, Maron DJ et al. COURAGE Investigators: Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008; 117: 1283-91.
14. Piepoli M, Hoes A, Agewall S et al. Wytyczne ESC dotyczące prewencji chorób układu sercowo-naczyniowego w praktyce klinicznej (2016). Kardiol Pol. 2016; 74(9): 821-936.
15. Borghi C, Cicero AF, Ambrosioni E. Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vasc Health Risk Manag. 2008; 4(3): 665-71.